Metronidazole disodium phosphate for injection

This product is a prodrug of metronidazole, which is hydrolyzed in the body to produce a corresponding amount of metronidazole. Metronidazole has a strong antibacterial effect on most anaerobic bacteria, but has no effect on aerobic bacteria and facultative anaerobes. The antibacterial spectrum includes Bacteroides fragilis and other Bacteroides, Fusobacterium, Clostridium perfringens, Eubacterium, Veillonella, Peptococcus and Peptostreptococcus. Its bactericidal concentration is slightly higher than the inhibitory concentration. The bactericidal mechanism of metronidazole has not been fully elucidated. The nitroreductase of anaerobic bacteria plays an important role in the energy metabolism of sensitive strains. The nitro group of this product is reduced to a cytotoxin, which acts on the DNA metabolism process of bacteria and promotes cell death.

The main ingredient of this product is metronidazole disodium phosphate. Chemical name: 2-methyl-5-nitroimidazole-1-ethanol-phosphate disodium salt monohydrate. Molecular formula: C6H8N3Na2O6PH2O Molecular weight: 313.12

This product is off-white or slightly yellow powder. It turns yellow gradually when exposed to light.

Used for various infectious diseases caused by anaerobic bacteria, such as sepsis, endocarditis, empyema, lung abscess, abdominal infection, pelvic infection, gynecological infection, bone and joint infection, meningitis, brain abscess, skin and soft tissue infection, etc.

Intravenous drip: 0.915 g at a time, dissolved in 100 ml of sodium chloride injection or 5% glucose injection, slowly dripped within 1 hour, once every 8 hours, 7 days as a course of treatment.

1. The most serious adverse reaction of this product is that it can cause epileptic seizures and peripheral neuropathy at high doses, the latter of which is mainly manifested as numbness and paresthesia of the extremities. In some cases, long-term use of the drug may cause persistent peripheral neuropathy. 2. Other common adverse reactions include: 1. Gastrointestinal reactions, such as nausea, loss of appetite, vomiting, diarrhea, abdominal discomfort, taste changes, dry mouth, metallic taste in the mouth, etc. 2. Reversible neutropenia. 3. Allergic reactions, rash, urticaria, itching, etc. 4. Central nervous system symptoms, such as headache, dizziness, syncope, paresthesia, limb numbness, ataxia and mental confusion. 5. Local reactions such as thrombophlebitis. 6. Others include fever, vaginal candidiasis, cystitis, difficulty urinating, dark urine color, etc., which are all reversible and will recover on their own after stopping the drug.

It is contraindicated for patients who are allergic to this product or azole drugs and those with active central nervous system diseases and blood diseases.

Precautions for children: Children should use it with caution and in reduced dosage. Precautions for pregnancy and lactation: The hydrolyzate metronidazole of this product can pass through the placenta and quickly enter the fetal circulation. Animal experiments have found that intraperitoneal administration is toxic to the fetus, while oral administration is non-toxic. There is no sufficient and strict control observation on the effect of this product on the fetus, so pregnant women are prohibited from using it. The concentration of metronidazole in breast milk is similar to that in blood. Animal experiments have shown that metronidazole is carcinogenic to young mice, so it is not suitable for lactating women. If the drug must be used, breastfeeding should be suspended, and breastfeeding can be resumed 24 to 48 hours after the end of the treatment.

1. This product can inhibit the metabolism of warfarin and other oral anticoagulants, enhance their effects, and cause the prothrombin time to be prolonged. 2. When used in combination with drugs that induce liver microsomal enzymes, such as phenytoin sodium and phenobarbital, it can enhance the metabolism of this product, reduce the blood drug concentration, and slow down the excretion of phenytoin sodium. 3. When used in combination with drugs that inhibit the activity of liver microsomal enzymes, such as cimetidine, it can slow down the metabolism and excretion of this product in the liver, prolong the blood elimination half-life (t1/2#61538;), and the dosage should be adjusted according to the results of blood drug concentration determination. 4. This product can interfere with the metabolism of disulfiram. When the two are used together, patients may experience mental symptoms after drinking. Therefore, patients who have used disulfiram within 2 weeks should not use this product again. 5. This product can interfere with the results of serum aminotransferase and lactate dehydrogenase determinations, and can reduce cholesterol and triglyceride levels.

Keep away from light and store in a sealed container.

0.915 g (equivalent to 0.862 g anhydrous)

24 months

CHIA TAI Tianqing Pharmaceutical Group Co., Ltd.

• Founded in:

  1997-04-16

• Address:

  No. 369, Yuzhou South Road, Lianyungang City, Jiangsu Province

• Tax NO.:

  91320000608398264T

• Registered Funds:

  890 million yuan

• Website:

  Log in to view

• Email:

  Log in to view